2023 saw a return to business as usual for the Federal Circuit. Oral arguments are once again in-person and open to the public, and the Court has resumed its former practice of holding occasional sittings outside of...more
2/9/2024
/ Administrative Procedure Act ,
Amgen v Sanofi ,
Appeals ,
Claim Construction ,
Copyright ,
Design Patent ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
International Trade Commission (ITC) ,
IP License ,
Obviousness ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Post-Grant Review ,
Prior Art ,
Proposed Rules ,
Regulatory Requirements ,
SCOTUS ,
Trademark Application ,
Trademark Litigation ,
Trademark Ownership ,
Trademark Registration ,
Trademarks ,
USPTO
PersonalWeb—the third appeal from a multidistrict litigation involving alleged infringement of PersonalWeb’s patents—addressed two issues: (1) whether the district court abused its discretion in finding the case exceptional...more
1/25/2024
/ Appeals ,
Dismissals ,
Innovation Patent ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Noninfringement ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Remand ,
Summary Judgment ,
Technology
Directors Michael Joffre, Ph.D., William H. Milliken, Anna G. Phillips, and Richard A. Crudo will present the webinar "Federal Circuit IP Appeals: Summaries of Key 2023 Decisions" on Tuesday, January 23, 2024, at 1:00 p.m....more
1/19/2024
/ Appellate Courts ,
Claim Construction ,
Continuing Legal Education ,
Design Patent ,
En Banc Review ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Obviousness ,
Patent Litigation ,
Patent Term Adjustment ,
Patents ,
Trademark Litigation ,
Webinars
Here, Hunting Titan petitioned for IPR of DynaEnergetics’ ’422 patent, asserting that the patent was anticipated in light of the Schacherer reference. The Board instituted the IPR and found all original claims unpatentable as...more
As part of the recovery from the global COVID-19 pandemic, the U.S. Court of Appeals for the Federal Circuit took steps to return to normal operations. It began requiring live oral arguments in August 2022 and, by November,...more
2/8/2023
/ § 314(d) ,
§ 315(b) ,
35 U.S.C. §315(e)(1) ,
Abuse of Discretion ,
Administrative Patent Judges ,
Administrative Procedure Act ,
America Invents Act ,
Anticipation ,
Apple ,
Appointments Clause ,
Arbitrary and Capricious ,
Arthrex Inc v Smith & Nephew Inc ,
Article III ,
Artificial Intelligence ,
Broadcom ,
Burden of Persuasion ,
Burden of Production ,
Confidentiality Agreements ,
Consent Order ,
Constitutional Challenges ,
Covenant Not to Sue ,
Director of the USPTO ,
Doctrine of Equivalents ,
Estoppel ,
Evidence ,
Ex Partes Reexamination ,
Expert Testimony ,
Failure To Disclose ,
Federal Vacancies Reform Act ,
Final Written Decisions ,
Forum Selection ,
Google ,
Indefiniteness ,
Intel ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
International Trade Commission (ITC) ,
Inventions ,
Inventors ,
Joint Inventors ,
Jurisdiction ,
Lack of Jurisdiction ,
Likelihood of Confusion ,
Motion to Amend ,
Motion to Terminate ,
Obviousness ,
Obviousness-Type Double Patenting (ODP) ,
Parallel Proceedings ,
Patent Act ,
Patent Applications ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patent Prosecution ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents ,
Post-Grant Review ,
Preliminary Injunctions ,
Preponderance of the Evidence ,
Prior Art ,
Qualcomm ,
Real Party in Interest ,
Remand ,
Section 101 ,
Section 112 ,
Separation of Powers ,
Standing ,
Statutory Authority ,
Sua Sponte ,
Substantial Evidence ,
Testimony ,
Time-Barred Claims ,
Trademark Application ,
Trademark Infringement ,
Trademark Litigation ,
Trademark Registration ,
Trademark Trial and Appeal Board ,
Trademarks ,
USPTO ,
Vacated ,
Written Descriptions
In conjunction with the release of the firm's year-in-review report, speakers will offer case summaries and analysis of the significant 2022 appellate rulings discussed in the report. Topics of the featured intellectual...more
1/23/2023
/ Consent Order ,
Continuing Legal Education ,
Estoppel ,
Expert Testimony ,
Final Written Decisions ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
International Trade Commission (ITC) ,
Obviousness ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Prior Art ,
Standing ,
Webinars
Intel Corp. petitioned for six inter partes reviews (IPRs) challenging the validity of U.S. Patent No. 9,608,675, a patent directed to power management in wireless devices. In each proceeding, Intel and patent-owner Qualcomm...more
3/2/2022
/ Administrative Procedure Act ,
Appeals ,
Burden of Proof ,
Claim Construction ,
Due Process ,
Final Written Decisions ,
Inter Partes Review (IPR) Proceeding ,
International Trade Commission (ITC) ,
Obviousness ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patent Validity ,
Patents ,
Prior Art ,
Remand ,
Sua Sponte ,
Vacated
[co-author: Jamie Dohopolski]
Last year, the continued global COVID-19 pandemic forced American courts to largely continue the procedures set in place in 2020. The U.S. Court of Appeals for the Federal Circuit was no...more
2/9/2022
/ § 314(d) ,
35 U.S.C. §315(e)(1) ,
Absolute Intervening Rights Doctrine ,
Abuse of Discretion ,
Administrative Patent Judges ,
Administrative Procedure Act ,
America Invents Act ,
Appeals ,
Appointments Clause ,
Arbitrary and Capricious ,
Article of Manufacture ,
Assignor Estoppel ,
Burden of Proof ,
Claim Construction ,
Collateral Estoppel ,
Commercial Success ,
Confidential Information ,
Constitutional Challenges ,
Demand Letter ,
Denial of Institution ,
Design Patent ,
Director of the USPTO ,
Dismissals ,
Doctrine of Prosecution Disclaimer ,
Due Process ,
Equitable Estoppel ,
Estoppel ,
Evidence ,
Ex Partes Reexamination ,
Executive Branch ,
Executive Powers ,
Federal Rules of Evidence ,
Final Written Decisions ,
Forum Selection ,
FRCP 52(c) ,
GATT ,
Inferior Officers ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Inter Partes Reexamination ,
Inter Partes Review (IPR) Proceeding ,
International Trade Commission (ITC) ,
Intervening Acts ,
Inventions ,
Issue Preclusion ,
Judicial Review ,
Lack of Authority ,
Lack of Jurisdiction ,
Likelihood of Success ,
Minerva Surgical Inc. v Hologic Inc. ,
Motion for Summary Judgment ,
Motivation to Combine ,
Nexus ,
Non-Disclosure Agreement ,
Nonobvious ,
Obviousness ,
Ornamental Design ,
Parallel Proceedings ,
Patent Applications ,
Patent Filings ,
Patent Infringement ,
Patent Litigation ,
Patent Prosecution ,
Patent Trial and Appeal Board ,
Patent Validity ,
Patents ,
Petition for Writ of Certiorari ,
Pharmaceutical Patents ,
Post-Grant Review ,
Pre-GATT ,
Preliminary Injunctions ,
Principle Officers ,
Printed Publications ,
Prior Art ,
Real Party in Interest ,
Remand ,
Reversal ,
Rule 36 ,
Scope of Review ,
SCOTUS ,
Section 325(d) ,
Sua Sponte ,
Substantial Evidence ,
Totality of Evidence ,
United States v Arthrex Inc ,
USPTO ,
Vacated ,
Writ of Mandamus
Adidas petitioned for inter partes reviews (IPR) of two Nike patents. The Patent Trial and Appeal Board concluded that Adidas had not met its burden to show that the challenged claims in Nike’s patents were obvious. Adidas...more
2/24/2021
/ Adidas ,
Article III ,
Inter Partes Review (IPR) Proceeding ,
Nike ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Standing ,
Substantial Evidence
Abbreviated new drug (ANDA) applicant Amneal petitioned for an inter partes review (IPR) of Almirall’s patent listed in the Food and Drug Administration’s (FDA) Orange Book for a prescription drug to treat acne. Almirall...more
2/23/2021
/ Abbreviated New Drug Application (ANDA) ,
Administrative Proceedings ,
Attorney's Fees ,
Covenant Not to Sue ,
Food and Drug Administration (FDA) ,
Inter Partes Review (IPR) Proceeding ,
Litigation Fees & Costs ,
Orange Book ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents
[co-author: Kathleen Wills]
Last year, the global COVID-19 pandemic created unprecedented challenges for American courts. By making several changes, however, the U.S. Court of Appeals for the Federal Circuit was able to...more
2/3/2021
/ Abbreviated New Drug Application (ANDA) ,
Adidas ,
Administrative Law Judge (ALJ) ,
Administrative Patent Judges ,
Administrative Proceedings ,
America Invents Act ,
Appeals ,
Appointments Clause ,
Certiorari ,
Claim Construction ,
Comcast ,
Constitutional Challenges ,
Corporate Counsel ,
Covenant Not to Sue ,
Denial of Certiorari ,
Dismissals ,
Due Process ,
Estoppel ,
Evidence ,
FanDuel ,
Final Written Decisions ,
Google ,
Hewlett-Packard ,
Hulu ,
Inter Partes Reexamination ,
International Trade Commission (ITC) ,
Judicial Review ,
Lack of Authority ,
Motion to Amend ,
Nike ,
Obviousness ,
Oral Argument ,
Patent Applications ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Post-Grant Review ,
Precedential Opinion ,
Real Party in Interest ,
Section 337 ,
Subject Matter Jurisdiction ,
Thryv Inc v Click-To-Call Technologies LP ,
Time-Barred Claims ,
United States v Arthrex Inc ,
USPTO
In 2019, the U.S. Court of Appeals for the Federal Circuit docketed just over 650 appeals from the U.S. Patent and Trademark Office (USPTO). That is the highest number since the Court started to hear post-American Invents Act...more